Combining new therapies for high-risk chronic lymphocytic leukemia
Official title: Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemia
Funded at Dana-Farber Cancer Inst · NIH-10890036 · Data updated 2026-11-12
This study is testing a new combination of three medicines to see if it can help people with high-risk chronic lymphocytic leukemia (CLL) who haven't started treatment yet, with the goal of making the cancer undetectable and improving their overall health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 15, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $383,236 |
| NIH project number | 5R01CA266298-03 |
| Project ID | NIH-10890036 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with previously untreated high-risk chronic lymphocytic leukemia, particularly those with TP53 aberrations.
✕Less likely to help
Patients with chronic lymphocytic leukemia who have already received treatment or do not have high-risk features may not benefit from this research.
What this research studies
This research investigates a new treatment approach for patients with high-risk chronic lymphocytic leukemia (CLL) who have not yet received treatment. It focuses on a combination of three agents: a BTK inhibitor, a BCL-2 inhibitor, and an anti-CD20 antibody, aiming to improve patient outcomes by achieving undetectable minimal residual disease. The study will evaluate the effectiveness and safety of this combination therapy through a clinical trial, while also exploring factors that may predict how well patients respond to the treatment.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for patients with high-risk CLL.
How similar studies have gone: Previous research has shown promising results with similar combination therapies in treating CLL, indicating potential for success in this novel approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Davids, Matthew S — Dana-Farber Cancer Inst
- Study coordinator: Davids, Matthew S
Related research
Other NIH-funded projects on the same topics.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
-
Understanding why BTK inhibitors stop working in chronic lymphocytic leukemia
Researchers are studying why some people with chronic lymphocytic leukemia stop benefiting from BTK inhibitors and how to overcome that resistance.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.